Healthcare Industry News: Restylane
News Release - June 10, 2016
Galderma Celebrates 20th Global Anniversary of Restylane(R)Restylane® Marks Heritage Milestone and Announces Innovative Syringe
FORT WORTH, Texas, June 10, 2016 -- (Healthcare Sales & Marketing Network) -- Galderma, a global leader focused on medical solutions in skin health, is proud to celebrate the significant milestone of the 20th global anniversary of the Restylane® portfolio of products1. One of the world's most studied wrinkle fillers2, Restylane has been used in more than 65 countries worldwide with over 28 million treatments administered globally2.
"The launch of the Restylane dermal filler in Europe in 1996 and in the United States in 2003 helped to change the aesthetic landscape. It quickly became a household name, and sparked a shift in how many of my patients approached facial aging," said Chicago-based physician Steve Dayan. "This anniversary not only celebrates 20 years of being a great option for men and women who want natural-looking results, but also serves as a proof point for how well-placed my trust is in the long track record of safety and efficacy of Restylane products in my practice."
After more than two decades of research, the complete line of Restylane fillers – including Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine and Restylane® Silk – have well-defined safety profiles3,4,5,6. With six major product approvals and four different indications, the Restylane family of products continues to deliver effective and proven aesthetic solutions to healthcare professionals and their patients allowing specialists to customize a treatment plan that's right for each individual3,4,5,6.
Innovative Syringe Delivers Enhanced Ergonomics and Safety
Building on the heritage of the milestones in the last 20 years, Galderma is committed to continuing its leadership role of Restylane innovation in the future.
Today, Galderma is proud to introduce a new, enhanced syringe for Restylane and Restylane Lyft. The new syringe will be available to practitioners during the second half of 2016. Key attributes of this new introduction include:
- A design focused on greater working comfort and enhanced ergonomics for the injector
- A state of the art design boasting sturdy construction and upgraded safety measures with a tamper-proof seal delivering heightened anti-counterfeiting protection for patient and clinician security
- Updated Restylane packaging designed to simplify product identification and selection
For more information about the Restylane family of products, visit www.RestylaneUSA.com.
Dating back to 1961, Galderma is now present in 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven treatment options for the skin, hair and nails.
Strategic brands in the U.S. include Epiduo® Gel, Epiduo® Forte Gel, Oracea® Capsules, Clobex® Spray, Differin® Gel, Mirvaso® Gel, MetroGel® Gel, Soolantra® Cream, Vectical® Cream, Tri-Luma® Cream, Cetaphil®, Benzac® Acne Solutions, Restylane®, Restylane® Silk, Restylane® Lyft and Sculptra® Aesthetic.
For more information, please visit www.galdermausa.com and www.galderma.com.
Important Safety Information
Indications: The Restylane family of products includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine and Restylane® Silk. Restylane, Restylane-L, and Restylane Lyft with Lidocaine are indicated for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane and Restylane-L are indicated for mid-to-deep dermal implantation. Restylane and Restylane-L are also indicated for submucosal implantation for lip augmentation in patients over the age of 21. Restylane Lyft with Lidocaine is indicated for implantation into the deep dermis to superficial subcutis. Restylane Lyft with Lidocaine is also indicated for cheek augmentation and for the correction of age-related midface contour deficiencies in patients over the age of 21.
Restylane Silk is indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
Products in the Restylane family contain traces of gram-positive bacterial protein and are contraindicated for patients with allergies to such material or in patients with severe allergies that have required in-hospital treatment. These products should not be used by patients with bleeding disorders or by pregnant or breastfeeding women. Restylane-L, Restylane Silk and Restylane Lyft with Lidocaine should not be used by anyone with a known allergy to lidocaine. Products should not be injected anywhere except areas indicated in their Instructions for Use.
Use of products in the Restylane family at the site of skin sores, pimples, rashes, hives, cysts, or infection should be postponed until healing is complete. The most commonly observed side effects are swelling, redness, pain, bruising, headache, tenderness, and itching at the injection site. These are typically mild in severity and typically resolve in less than 7 days in nasolabial folds and less than 14 days in lips. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site. Do not implant into blood vessels. Use with caution in patients recently treated with anticoagulant or platelet inhibitors to avoid bleeding and bruising.
The Restylane family of products is available only through a licensed practitioner. Complete Instructions for Use are available at www.RestylaneUSA.com.
1 Q-Med. Restylane approval [press release]. October 23, 1996.
2 Data on file. Galderma.
3 Restylane® Product & Safety Information.
4 Restylane-L® Product & Safety Information.
5 Restylane® Silk Product & Safety Information.
6 Restylane® Lyft with Lidocaine Product & Safety Information.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.